Unlock instant, AI-driven research and patent intelligence for your innovation.

Tirofiban degradation impurity, preparation method and application thereof

A technology of tirofiban, quality control method, applied in the field of degrading impurities of tirofiban and its preparation, capable of solving problems such as injury, insufficiency, toxic and side effects

Inactive Publication Date: 2021-10-22
GRAND PHARM (CHINA) CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the research on the degraded impurities of tirofiban is not sufficient, especially the degraded impurities with high toxicity and greater harm, such as genotoxic impurities, which can cause harm to the body at a very low content, so it may cause toxicity. side effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tirofiban degradation impurity, preparation method and application thereof
  • Tirofiban degradation impurity, preparation method and application thereof
  • Tirofiban degradation impurity, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0059] According to a specific embodiment of the present invention, high performance liquid chromatography detection condition is as follows:

[0060]

[0061]

[0062] The compound structure shown in formula I is as follows:

[0063]

[0064] According to a specific embodiment of the present invention, before using the high performance liquid chromatography for separation, the solution containing the compound represented by formula I is treated as follows:

[0065] adjusting the pH value of the solution containing the compound represented by formula I to 6-8, and performing extraction treatment with ethyl acetate to obtain an ethyl acetate layer and an aqueous layer;

[0066] Concentrating the ethyl acetate layer to obtain a concentrate, dissolving the concentrate with an aqueous acetonitrile solution to obtain a sample solution;

[0067] The sample solution and the water layer were separated by high performance liquid chromatography, and fractions containing the co...

Embodiment 1

[0074] The acquisition of embodiment 1 impurity

[0075] Preparation of degradation solution: Weigh about 250 mg of tirofiban hydrochloride sample (crude drug, produced by Wuhan Wuyao), put it in a 1-liter volumetric flask, add water to dissolve it completely, dilute to the mark, and shake well. Take 5ml of this solution and place it in a 20ml headspace bottle, add 5ml of 2M HCl solution, shake well, and seal it with a press cap. In this manner, 1 L of the prepared solution was dispensed into 200 20 ml headspace vials. Place the headspace bottle in an oven at 90°C for 4 hours, take it out, and let it cool to room temperature. All solutions were then transferred to 2 L containers as preparative degradation solutions. The degradation solution is divided into two parts, which are processed in the following ways (1) and (2) respectively:

[0076] (1) Part of the above degradation solution is rotary evaporated under reduced pressure to remove part of the water and hydrochloric a...

Embodiment 2

[0084] Embodiment 2 Identification of impurity structure

[0085] Combined with HPLC, HRMS, NMR, the structure identification of the impurity obtained in Example 1 was carried out.

[0086] The HPLC detection conditions are as follows in Table 3:

[0087] table 3

[0088]

[0089] attached figure 1 The HPLC detection results are shown, and the results show that under the degradation conditions of Example 1, two degradation impurities MS475 (3-chloro-tirofiban) and MS262 are produced, and the retention times are 27.1min and 26.6min respectively. It can be seen that tirofiban and 3-chloro-tirofiban can be effectively separated by adopting this method.

[0090] The structure of the impurity was identified by HRMS and NMR.

[0091] HRMS test conditions are shown in Table 4:

[0092] Table 4

[0093]

[0094]

[0095] figure 2 The HRMS detection results are shown, and the results show that the molecular weight of the impurity under high-resolution mass spectrometr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of pharmacy, in particular to a tirofiban degradation impurity I, a preparation method and application thereof. According to the invention, a new tirofiban degradation impurity is found, and whether the quality of the tirofiban injection reaches the standard or not is determined by measuring the content of the tirofiban degradation impurity in the tirofiban injection, so that quality control over the tirofiban injection is achieved.

Description

technical field [0001] The invention relates to the technical field of pharmacy, in particular, the invention relates to a tirofiban degraded impurity and a preparation method and application thereof. Background technique [0002] Tirofiban (Tirofiban), alias tirofiba, chemical name N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine, molecular formula C 22 h 36 N 2 o 5 S, developed by Merck in the United States, was launched in the United States in 1998 and was approved for listing in China in August 2004. Tirofiban is an antiplatelet drug, clinically mainly used for coronary angioplasty or intracoronary plaque resection in patients with coronary ischemic syndrome, in order to prevent and treat related cardiac ischemic complications; Patients with stable angina or non-Q wave myocardial infarction (combined with heparin or aspirin), to prevent the occurrence of cardiac ischemic events. Tirofiban hydrochloride injection, which is a reversible non-peptide platelet sur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D211/22G01N30/02
CPCC07D211/22G01N30/02
Inventor 王芝蔡一聪秦巨波刘孟于艳春
Owner GRAND PHARM (CHINA) CO LTD